Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, updates us on novel therapies in acute myeloid leukemia (AML) and the evolving treatment landscape. Dr Cerchione discusses the use of CPX-351 in patients with secondary AML as well as the use of combination therapies to improve the outcomes of patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).